3 Growth Stocks with Insider Backing to Thrive in Volatile Markets

In a market rife with uncertainty, investors often seek companies where executives and insiders are putting their money where their mouth is. Three standout stocks—Astera Labs (ALAB), CoreWeave (CRWV), and Corcept Therapeutics (CORT)—combine insider ownership as a confidence signal with staggering earnings growth forecasts, positioning them as resilient plays in AI-driven infrastructure and healthcare innovation. Here's why these companies are worth a closer look before opportunities narrow.

Astera Labs (ALAB): The AI Infrastructure Play with 15.8% Insider Ownership

Astera Labs, a leader in high-performance silicon for AI data centers, has 15.8% insider ownership, including its founders and executives. This concentration reflects confidence in its strategic partnerships, most notably with NVIDIA, which is accelerating demand for its chip solutions.

Why It's a Buy:
- Earnings Growth: ALAB's net income surged to $31.8 million in Q1 2025, marking a historic turnaround from years of losses. Analysts project 44.3% annual earnings growth over the next three years, driven by AI adoption and cloud infrastructure spend.
- Valuation: Trading at a 15x price-to-sales (P/S) ratio, ALAB is undervalued relative to its $159 million in Q1 revenue and its role in NVIDIA's ecosystem.
- Insider Activity: Despite minor sales by directors in early 2025, insider ownership remains steady, signaling long-term commitment.

CoreWeave (CRWV): The AI Hyperscaler with 19.9–38.1% Insider Ownership

CoreWeave, an AI cloud infrastructure giant, boasts 19.9–38.1% insider ownership, with CEO Michael Intrator and executives holding stakes worth over $1.5 billion. This alignment of interests underscores confidence in its exponential growth trajectory.

Why It's a Buy:
- Earnings Growth: Q1 2025 revenue soared 420% year-over-year to $981 million, fueled by its $11.2 billion deal with OpenAI and enterprise AI adoption. Analysts predict 70.3% annual earnings growth, with a $25.9 billion revenue backlog as of March 2025.
- Valuation: Despite a recent pullback, CoreWeave's Adjusted EBITDA margins hit 62% in Q1, signaling scalability even as it invests in growth.
- Insider Activity: While some insiders sold shares in late 2024, ownership remains robust, and CEO Intrator has doubled down on long-term holdings.

Corcept Therapeutics (CORT): The Pharma Innovator with 11.7% Insider Ownership

Corcept, a biotech firm developing cortisol-modulating drugs, has 11.7% insider ownership, including CEO Joseph Korb, who increased his stake in 2023. Its pipeline is its crown jewel.

Why It's a Buy:
- Earnings Growth: With its lead drug relacorilant in late-stage trials for ovarian cancer and Cushing's syndrome, analysts project 35.1% annual earnings growth. Revenue guidance of $900–950 million for 2025 supports this outlook.
- Valuation: At a $3 billion market cap, Corcept is undervalued given relacorilant's potential. Success in late-stage trials could unlock a multi-billion-dollar market.
- Insider Activity: No major insider sales in 2025, with Korb's prior purchases signaling belief in the drug's trajectory.

Why These Stocks Are Undervalued—and Why to Act Now

All three companies operate in high-growth sectors with secular tailwinds:
1. Astera Labs benefits from AI's insatiable demand for compute power.
2. CoreWeave is a direct beneficiary of OpenAI's expansion and enterprise AI adoption.
3. Corcept targets a niche pharmaceutical market with high margins and unmet needs.

While valuations are reasonable (ALAB's 15x P/S vs. peers at 20–30x), these stocks carry risks:
- CoreWeave's net losses (due to scaling costs) could pressure short-term sentiment.
- Corcept's clinical trial results for relacorilant are critical to its valuation.

Investment Recommendation

These stocks are contrarian bets in a volatile market. Insider ownership acts as a “shield,” and their earnings growth trajectories suggest 28–44% annual returns over three years.

• Astera Labs (ALAB): Ideal for investors focused on AI infrastructure and undervalued tech.
• CoreWeave (CRWV): Best for those willing to ride out near-term losses for long-term AI hyperscaler dominance.
• Corcept (CORT): A healthcare play with binary event risk (drug approvals) but asymmetric upside.

Act now: These opportunities won't stay open for long as earnings growth materializes and Wall Street catches on.

Investment advice is for informational purposes only. Always conduct your own research.